Skip to content
Screener

Upstream Bio, Inc. UPB Financing Cash Flow

Financing Cash Flow at other companies

Amgen logo
AmgenAMGN
-$1.48B+44.6%
Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
-$1.22B-8.5%
Aclaris Therapeutics logo
Aclaris TherapeuticsACRS
$91K+1,111%
Shattuck Labs, Inc. logo
Shattuck Labs, Inc.STTK
$128.01M
Savara logo
SavaraSVRA
-$195K-108%
AnaptysBio, Inc. logo
AnaptysBio, Inc.ANAB
$1.21M+104%

Other financials

Income statement

See full
Revenue$773.0K-17.5%
Operating income-$42.4M+4.5%
Net income-$39.7M+0.7%
EPS (diluted)-$0.73+1.4%

Balance sheet

See full
Cash & equivalents$79.4M+74.7%
Total debt$954.0K-38.9%
Total equity$271.0M-33.7%
Total assets$281.2M-33.1%

Cash flow

See full
Operating cash flow-$35.6M+9.2%
CapEx$54.0K-70.8%
Free cash flow-$30.7M-55.0%

Valuation

See full
Market cap$394.54M-54.7%
Enterprise value$316.1M-61.6%
P/S124.9×-195×

Profitability

See full
Operating margin-5,382.6%+1,393pp
Net margin-4,955.7%+2,041pp

Returns & leverage

See full
Return on equity-46%
Debt / equity0.0×
Current ratio28×-10.3×

Where this comes from

Reported directly by Upstream Bio, Inc. in its filing.

Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInFinancingActivities.

The source filing: Upstream Bio, Inc.’s 10-Q, filed August 11, 2026.

Filed
Aug 11, 2026, 7:10 AM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001193125-26-343417
Line itemSix Months Ended June 30, 2026Six Months Ended June 30, 2025
Proceeds from issuance of common stock in connection with at-the-market offering, net of commissions2,083
Proceeds from issuance of common stock under stock plans1,048612
Payments of initial public offering costs(34)
Net cash provided by financing activities3,131578
Net decrease in cash, cash equivalents and restricted cash(22,181)(280,434)
Cash, cash equivalents and restricted cash at beginning of period101,772326,086
Cash, cash equivalents and restricted cash at end of period$79,591$45,652
Cash, cash equivalents and restricted cash at end of period:

Item 1. Financial Statements.

FAQ

What is Upstream Bio, Inc.'s financing cash flow?
Upstream Bio, Inc. (UPB) reported financing cash flow of $2.53M in Q2 2026.
How has Upstream Bio, Inc.'s financing cash flow changed year-over-year?
Upstream Bio, Inc.'s financing cash flow increased by 313.9% year-over-year, from $612K to $2.53M.
What is the long-term trend for Upstream Bio, Inc.'s financing cash flow?
Over 2 years (2023 to 2025), Upstream Bio, Inc.'s financing cash flow has grown at a -86.3% compound annual growth rate (CAGR), from $129.55M to $2.44M.
What does financing cash flow mean?
Total net cash provided by or used in financing activities — debt issuance/repayment, equity transactions, and dividend payments.

Ask your AI about Upstream Bio, Inc.'s financing cash flow.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude